High HMGN1 levels drive leukemia in Down syndrome
Nature Genetics
2014년4월21일
A genetic cause of the link between Down syndrome and B cell acute lymphoblastic leukemia (B-ALL) in both mice and human cells is reported in a paper published online this week in Nature Genetics. The study identifies a promising drug target to treat B-ALL in Down syndrome.
People with Down syndrome are at a 20-fold risk of developing a type of B-ALL, an aggressive cancer of the white blood cells. David Weinstock and colleagues found that having three copies of a small region of 31 genes on chromosome 21 was sufficient to drive the cancer. Using a combination of experiments in mice and human cells, they found that increased levels of a specific protein, HMGN1, turns on the group of genes needed for the cancer to spread. The increase in HMGN1 levels was specific to Down syndrome B-ALL, but not other types of ALL.
The authors speculate that drugs that inhibit HMGN1 could prove useful for treating B-ALL in Down syndrome patients.
doi: 10.1038/ng.2949
리서치 하이라이트
-
10월26일
Archaeology: Layout of ancient Mesoamerica sites revealed by remote sensingNature Human Behaviour
-
10월19일
Physiology: Fasting may mediate the beneficial effects of calorie restriction in miceNature Metabolism
-
10월14일
Climate change: Global energy spending changes in a warming worldNature
-
10월14일
Epidemiology: Tracking the evolution and spread of SARS-CoV-2 in EnglandNature
-
10월13일
Health: El Niño associated with child undernutrition in the tropicsNature Communications
-
10월12일
Archaeology: Earliest known human use of tobacco revealedNature Human Behaviour
